EVENITY ™ (romosozumab-aqqg) now available in the United States for the treatment of osteoporosis in postmenopausal women at high risk for fracture

Amgen (NASDAQ: AMGN) announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on April 9, 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news